medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2003, Number 4

<< Back Next >>

Salud Mental 2003; 26 (4)

Determination of hypericin and hyperforin content in different phytopharmaceuticals and dietary supplements containing Hypericum perforatum extract

Tortoriello J, Zamilpa A, Herrera A, Romero-Cerecero O

Language: English
References: 25
Page: 59-63
PDF size: 372.74 Kb.


ABSTRACT

Background: Phytopharmaceuticals have long been used as official medicine in different countries around the world. In Mexico, they were recently introduced. One of the most prescribed phytopharmaceuticals is derived from the Hypericum perforatum species. This plant, commonly known as St. John´s Wort, is widely used in traditional herbal medicine for wound healing and as an antidepressant. Several clinical and pharmacological works have demonstrated the efficacy and safety of extracts prepared from the aerial parts of this plant in the treatment of mild to moderate depression. This activity has been attributed to hyperforin, hypericin and flavonic compounds. For many years, the naphtodianthrone, hypericin, was considered as the main active constituent. Nevertheless, it has been demonstrated that the acylphloroglucinol, hyperforin together with hypericin and some flavonic compounds are the active antidepressant compounds. Since depressive disorders are very common in clinical practice, with approximately 11.3% of all adults being afflicted by these disorders during any one year, different preparations of St. John´s Wort are available as phytopharmaceuticals and dietary supplements in different countries, including Mexico.
Methods: In order to compare different phytopharmaceuticals and dietary supplements containing H. perforatum extract available in Mexico, the total content of hypericin and hyperforin was determined. Three products were purchased in pharmacies as phytopharmaceuticals (S1, S2, S3), while four products were available as dietary supplements (S4, S5, S6, S7).
Results: Phytopharmaceuticals were found as coated tablets or gelatin capsules with individual packing in aluminum blisters, while dietary supplements were all found as uncoated tablets in glass or plastic bottles. With the exception of one product (S4), in all samples detectable amounts of hypericin were found. Products S2, S3, and S7 had a higher hypericin content (between 0.2% and 0.26%). Most of the samples analyzed had no detectable amounts of hyperforin. The products S1 and S7 contained only trace quantities of hyperforin, while products S2 and S3 had the highest amount with more than 4.0% and 2.5%, respectively.
Conclusions: Although all of the products studied contained the extract of H. perforatum as a main constituent, there were marked differences between them. It was observed that the formulation (coated tablets) packing (individual packing in aluminum blisters) and active constituents content (hypericin and hyperforin) of the phytopharmaceuticals differ significantly from that of the dietary supplements.


REFERENCES

  1. BARNES J, ANDERSON LA, PHILLIPSON JD: St. John´s wort (Hypericum perforatum L): A review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol, 53:583-600, 2001.

  2. BIBER A, FISCHER H, RÖMER A, CHATERJEE SS: Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry, 31 (Supl. 1):36-43, 1998.

  3. BILIA AR, BERGONZI MC, MORGENNI F, MAZZI G, VINCIERI FF: Evaluation of chemical stability of St. John´s wort commercial extract and some preparations. Int J Pharm, 213:199-208, 2001.

  4. BUTTERWECK V, WALL A, LIEFLÄNDER-WULF U, WINTERHOFF H, NAHRSTEDT A: Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry, 30 (Supl. 2):117-124, 1997.

  5. CHATTERJEE SS, KOCH E, NÖLDNER M, BIBER A, ERDELMEIER C: Hyperforin and hypericum extract: Interactions with some neurotransmitter systems. Phytomedicine, 3(Supl. 1):106, 1996.

  6. CHATTERJEE SS, NÖLDNER M, KOCH E, ERDELMEIER C: Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry, 31(Supl. 1):7-15, 1998.

  7. ERDELMEIER CA: Hyperforin, possibly the major nonnitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry, 31(Supl. 1):2-6, 1998.

  8. ERNST E: St. John’s wort, an antidepressant? A systematic, criteria based review. Phytomedicine, 2:67-71, 1995.

  9. GAEDCKE F: Johanniskraut und dessen Zubereitungen. Deutsche Apotheker Zeitung, 137:3753-3757, 1997.

  10. GREESON JM, SANFORD B, MONTI DA: St. John´s wort (Hypericum perforatum): a review of the current pharmacological, toxicological and clinical literature. Psychopharmacology, 153:402-414, 2001.

  11. HARRER G, HÜBNER WD, PODZUWEIT H: Effectiveness and tolerance of the hypericum extract L1 160 compared to maprotiline: a multicenter, double-blind study. J Geriatr Psychiatry Neurol, 7(supl. 1):24-28, 1994.

  12. HÜBNER WD, KIRSTE T: Experience with St. John´s wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res, 15:367-370, 2001.

  13. JUDD LL: Mood disorders in the general population represent an important and worldwide public health problem. Int Clin Psychopharmacol, 10(Supl. 4):5-10, 1995.

  14. KASPER S: Hypericum perforatum – A review of clinical studies. Pharmacopsychiatry, 34(Supl. 1):51-55, 2001.

  15. KÄUFELER R, MEIER B, BRATTSTRÖM A: Efficacy and tolerability of Ze 117 St. John´s wort extract in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10. An overview. Pharmacopsychyatry, 34 (Supl. 1):49-50, 2001.

  16. KERB R, BROCKMÖLLER J, STAFFELDT B, PLOCH M, ROOTS I: Single dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother, 40:2087-2093, 1996.

  17. LAAKMANN G, SCHÜLE C, BAGHAI T, KIESER M: St. John´s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry, 31(Supl. 1):54-59, 1998.

  18. Ley General de Salud. Reglamento de Insumos para la Salud. Ed. Porrua, México, 2000.

  19. MÜLLER WE: St. John´s wort (Hypericum), story goes on. Pharmacopsychiatry, 31(Supl. 1):1, 1998.

  20. MÜLLER WE, SINGER A, WONNEMANN M, HAFNER U, ROLLI M, SCHÄFER C: Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry, 31 (Supl. 1):16-21, 1998.

  21. NATHAN PJ: Hypericum perforatum (St John´s wort): a nonselective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol, 15:47-54, 2001.

  22. POWDER ED: St. John’s wort extract. Pharmacopeial Forum, 26:464, 2000.

  23. TORTORIELLO J: Neurophytopharmaceuticals: A review; En: Lozoya X, Gomez E, Brunner M (eds.) Simposium IMSSFarmasa Schwabe, México, 77-98, 1999.

  24. WERTH W: Psychotonin M versus imipramin in der chirurgie. Der Kassenarzt, 15:64-68, 1989.

  25. WHEATLEY D: LI 160, an extract of St John´s wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry, 30(Supl. 2):77-80, 1997.




2020     |     www.medigraphic.com